



American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) 2022; San Francisco, CA (Hybrid): Eisai Inc. Sponsored Research

Please see the listing of Eisai Inc. sponsored research presented at ASCO GI 2022 below.

GASTROESOPHAGEAL ADENOCARCINOMA

1. Cohen DJ, Tabernero J, Van Cutsem E, et al. A Randomized Phase 3 Study Evaluating the Efficacy and Safety of First-line Pembrolizumab plus Lenvatinib plus Chemotherapy versus Chemotherapy in Patients with Advanced/metastatic Gastroesophageal Adenocarcinoma: LEAP-015. Poster presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI); January 20-22, 2022; San Francisco, California (Hybrid).

HEPATOCELLULAR CARCINOMA

1. El-Khoueiry AB, Llovet JM, Vogel A, et al. LEAP-012 Trial in Progress: Transarterial Chemoembolization (TACE) With or Without Lenvatinib plus Pembrolizumab for Intermediate-stage Hepatocellular Carcinoma not Amenable to Curative Treatment. Poster presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI); January 20-22, 2022; San Francisco, California (Hybrid).
2. Peck-Radosavljevic M, Goyal L, Strassar S, et al. A Multicenter, Observational, Phase 4 Study (STELLAR) to Evaluate the Safety and Tolerability of Lenvatinib in Patients With Advanced or Unresectable Hepatocellular Carcinoma. Poster presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI); January 20-22, 2022; San Francisco, California (Hybrid).
3. Ueshima K, Ishikawa T, Saeki I, et al. Transcatheter Arterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma (TACTICS-L) in Japan: Primary Analysis. Poster presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI); January 20-22, 2022; San Francisco, California (Hybrid).

ESOPHAGEAL SQUAMOUS CELL CARCINOMA

1. Sun JM, Enzinger P, Adenis A, et al. LEAP-014: An Open-label, Randomized, Phase 3 Study of First-line Lenvatinib plus Pembrolizumab plus Chemotherapy in Esophageal Squamous Cell Carcinoma. Poster presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI); January 20-22, 2022; San Francisco, California (Hybrid).

SOLID TUMORS

1. Kelley RK, Van Cutsem E, Lee MS, et al. Phase 2, Open-label Study of Pembrolizumab plus Lenvatinib and Belzutifan in Patients with Advanced Solid Tumors. Poster presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI); January 20-22, 2022; San Francisco, California (Hybrid).

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the publication(s) listed above, please submit your request via www.eisaimedicalinformation.com/oncology/medicalinquiry or the submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_oncmedinfo@eisai.com or call 1-888-274-2378.